{"_buckets": {"deposit": "b2e3d66a-3ba8-42d3-bda5-bc593836c3ac"}, "_deposit": {"id": "3157", "owners": [], "pid": {"revision_id": 0, "type": "recid", "value": "3157"}, "status": "published"}, "_oai": {"id": "oai:meral.edu.mm:recid/3157", "sets": ["user-um1"]}, "communities": ["um1"], "item_1583103067471": {"attribute_name": "Title", "attribute_value_mlt": [{"subitem_1551255647225": "Effect of GSTP1 polymorphism on efficacy and safety of cyclophosphamide aggressive therapy in lupus nephropathy patients", "subitem_1551255648112": ""}]}, "item_1583103085720": {"attribute_name": "Description", "attribute_value_mlt": [{"interim": "\u003cp\u003eBackground Lupus nephritis (LN) occurs in up to 60% of adults with systemic lupus erythematosus (SLE) and is a predictor\u003cbr\u003e\nof poor survival. Cyclophosphamide (CYC) is regarded as the most effective immunosuppressive medication to improve\u003cbr\u003e\nsurvival for patients with LN.\u003cbr\u003e\nObjective This prospective hospital-based study was conducted to identify the effect of glutathione S transferase Pi-1\u003cbr\u003e\n(GSTP1) genotypes on the efficacy and safety of CYC aggressive therapy.\u003cbr\u003e\nMethods We enrolled SLE nephropathy patients admitted to the Department of Rheumatology of the 500-bed Yangon\u003cbr\u003e\nSpecialty Hospital (YSH), Yangon, Myanmar, who received CYC aggressive therapy for 6 months according to treatment\u003cbr\u003e\nguidelines for SLE patients with renal involvement. The frequencies of I/I, I/V and V/V GSTP1 genotypes were determined\u003cbr\u003e\nusing the polymerase chain reaction-restriction fragment length polymorphism method. The efficacy of CYC aggressive\u003cbr\u003e\ntherapy between LN patients with wild GSTP1 (I/I) and those with polymorphic GSTP1 (I/V or V/V) genotypes was evaluated\u003cbr\u003e\nby comparing 24-h urinary protein levels and assessing the remission rates at 3 and 6 months after initiation of CYC.\u003cbr\u003e\nCYC-related myelotoxicity was assessed by reviewing complete blood picture results on the 10th day after CYC treatment.\u003cbr\u003e\nResults In total, 95 eligible patients were recruited. The frequencies of I/I, I/V and V/V GSTP1 genotypes were 54.7, 41.1\u003cbr\u003e\nand 4.2%, respectively. At 3 and 6 months after CYC treatment, mean 24-h urinary protein had significantly decreased from\u003cbr\u003e\nbaseline in both wild and polymorphic genotype groups (p \u0026lt; 0.001). No significant differences were seen between the wild\u003cbr\u003e\nand polymorphic genotype groups with regard to changes in 24-h urinary protein levels, remission at 3 and 6 months or\u003cbr\u003e\nmyelotoxicity.\u003cbr\u003e\nConclusion CYC aggressive therapy had similar efficacy and caused no significant differences in myelotoxicity in wild GSTP1\u003cbr\u003e\n(I/I) and polymorphic GSTP1 (I/V or V/V) genotypes in patients treated according to YSH guidelines for SLE patients with\u003cbr\u003e\nrenal involvement.\u003c/p\u003e"}]}, "item_1583103108160": {"attribute_name": "Keywords", "attribute_value": []}, "item_1583103120197": {"attribute_name": "Files", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_access", "date": [{"dateType": "Available", "dateValue": "2019-11-18"}], "displaytype": "preview", "download_preview_message": "", "file_order": 0, "filename": "thu2019.pdf", "filesize": [{"value": "746 Kb"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_0", "mimetype": "application/pdf", "size": 746000.0, "url": {"url": "https://meral.edu.mm/record/3157/files/thu2019.pdf"}, "version_id": "fce00ab7-7c13-4ffc-bd84-44dc55095d75"}]}, "item_1583103131163": {"attribute_name": "Journal articles", "attribute_value_mlt": [{"subitem_issue": "", "subitem_journal_title": "Drugs \u0026 Therapy Perspectives", "subitem_pages": "334-340", "subitem_volume": "35"}]}, "item_1583103147082": {"attribute_name": "Conference papers", "attribute_value_mlt": [{"subitem_acronym": "", "subitem_c_date": "", "subitem_conference_title": "", "subitem_part": "", "subitem_place": "", "subitem_session": "", "subitem_website": ""}]}, "item_1583103211336": {"attribute_name": "Books/reports/chapters", "attribute_value_mlt": [{"subitem_book_title": "", "subitem_isbn": "", "subitem_pages": "", "subitem_place": "", "subitem_publisher": ""}]}, "item_1583103233624": {"attribute_name": "Thesis/dissertations", "attribute_value_mlt": [{"subitem_awarding_university": "", "subitem_supervisor(s)": [{"subitem_supervisor": ""}]}]}, "item_1583105942107": {"attribute_name": "Authors", "attribute_value_mlt": [{"subitem_authors": [{"subitem_authors_fullname": "K. Khine Thu"}, {"subitem_authors_fullname": "Aye Aye Lwin"}, {"subitem_authors_fullname": "Khin Than maw"}, {"subitem_authors_fullname": "Lei Lei Htay"}, {"subitem_authors_fullname": "Khin Mar Myint"}, {"subitem_authors_fullname": "Myat Myat Soe"}, {"subitem_authors_fullname": "Ye Htut Linn"}, {"subitem_authors_fullname": "Chit Soe"}, {"subitem_authors_fullname": "Nang Hla Hla Win"}]}]}, "item_1583108359239": {"attribute_name": "Upload type", "attribute_value_mlt": [{"interim": "Publication"}]}, "item_1583108428133": {"attribute_name": "Publication type", "attribute_value_mlt": [{"interim": "Journal article"}]}, "item_1583159729339": {"attribute_name": "Publication date", "attribute_value": "2019-11-18"}, "item_1583159847033": {"attribute_name": "Identifier", "attribute_value": "10.5281/zenodo.3545674"}, "item_title": "Effect of GSTP1 polymorphism on efficacy and safety of cyclophosphamide aggressive therapy in lupus nephropathy patients", "item_type_id": "21", "owner": "1", "path": ["1596631759527"], "permalink_uri": "http://hdl.handle.net/20.500.12678/0000003157", "pubdate": {"attribute_name": "Deposited date", "attribute_value": "2019-11-18"}, "publish_date": "2019-11-18", "publish_status": "0", "recid": "3157", "relation": {}, "relation_version_is_last": true, "title": ["Effect of GSTP1 polymorphism on efficacy and safety of cyclophosphamide aggressive therapy in lupus nephropathy patients"], "weko_shared_id": -1}